Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds
Executive Summary
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.
You may also be interested in...
Delisting Of Jazz’s Xyrem Patent In Orange Book Could Spur More Infringement Counterclaims
Jazz’s REMS patent on distribution of Xyrem does not belong in the Orange Book because it is directed to systems rather than a method of using the drug, court rules, agreeing with FTC’s analysis.
Delisting Of Jazz’s Xyrem Patent In Orange Book Could Spur More Infringement Counterclaims
Jazz’s REMS patent on distribution of Xyrem does not belong in the Orange Book because it is directed to systems rather than a method of using the drug, court rules, agreeing with FTC’s analysis.
Possible Orange Book Revisions Back In Play With US FDA Report To Congress
Agency is setting up an internal working group to assess whether certain patent information should be included or removed from the Orange Book. PhRMA, AAM and others address therapeutic equivalence ratings and listing of device-related and REMS-related patents.